We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
After a spectacular January, the second month of 2019 also turned out positive for Wall Street with SPDR S&P 500 ETF (SPY - Free Report) , SPDR Dow Jones Industrial Average ETF (DIA - Free Report) and Invesco QQQ ETF (QQQ - Free Report) adding about 3.4%, 4% and 3.7%, respectively. Overall, the broader market was charged up and iShares Core S&P Total US Stock Mkt ETFITOT gained about 6.1% past month (as of Feb 27, 2019).
In fact, February’s performance positioned the S&P 500 for its best year-to-date performance in more than three decades, per financial times. The S&P 500 has recoiled sharply this year from the Christmas slump and is now less than 5% away from its record high five months ago as indicated by financial times.
Against this backdrop, let’s delve a little deeper into the key ETF events of February that helped Wall Street maintain its 2019 mojo.
Dovish Fed
The Fed minutes from the Jan 29-30 meeting confirms the patient view of the central bank toward future rates hike. The Fed started offering a dovish tone from the start of this year, which is one of key reasons for the market rally. A dovish Fed has kept Invesco DB US Dollar Bullish (UUP) (up 0.6% past month) at a subdued level.
U.S.-China Trade Relation: Peaks & Valleys
Apparently, the month was all about U.S.-China trade optimism. On Feb 25, President Donald Trump even announced a delay in the increase of tariffs to 25% on about $200 billion worth of Chinese goods, citing “substantial progress” in trade talks with Beijing (read: Top Performing ETF Areas of February).
With this, the year-long trade dispute between the world’s biggest economies was thought to be reaching a conclusion. However, there was skepticism too in the U.S.-China trade relation. At month-end, U.S. trade representative Robert Lighthizer told Congress that the disagreement between both countries “was too serious to be solved by promises by China to buy more US products.”
Whatever the case, China ETFs were clear winners in the month. Global X MSCI China Information Tech ETFCHIK, VanEck Vectors ChinaAMC SME-ChiNext ETF (CNXT - Free Report) and VanEck Vectors ChinaAMC CSI 300 ETF returned in the range of 15% to 20%.
Zero-Fee ETF to Hit Market?
In late February, Social Finance Inc., an online lender also known as SoFi, made headlines by proposing two ETFs that will waive off managed fees for at least the first year of operation. Not only this, renowned issuer Vanguard also cut fees of the 10 key ETFs like Vanguard FTSE Emerging Markets ETF (VWO - Free Report) as part of the ongoing fee war trend (read: Zero-Fee ETFs to Hit the Market Finally?).
M&A Holds Up Biotech Sector
A solid merger-and-acquisition momentum has been instrumental in the biotech rally this year. February was no exception as Swiss pharma giant Roche Holdings (RHHBY - Free Report) announced the acquisition of the U.S.-based gene therapy company Spark Therapeutics for $4.8 billion (read: Biotech ETFs Jump on Roche-Spark Deal).
Principal Healthcare Innovators Index ETF BTEC, ALPS Medical Breakthroughs ETF (SBIO - Free Report) and Virtus LifeSci Biotech Products ETFBBP are some of the winners in the month, having gained around 10% each.
Marijuana Maintains its Mojo
Pot stocks are on a tear this year on positive industry-specific news and renewed risk appetite. February’s key tailwind in the marijuana market was Canadian cannabis firm Tilray Inc.’sTLRY announcement of acquisition of the world’s largest hemp food maker Manitoba Harvest for $318 million. Growing efforts of inducing cannabis in food, beverage, tobacco and beauty products explain the 15% one-month gains in ETFMG Alternative Harvest ETFMJ (read: Tilray's Deal to Buy Hemp Food Maker Bolsters Marijuana ETF).
Busy U.S. IPO Market
Just as the government reopened, the U.S. IPO market charged up in February. In late February, Up Fintech and NASH biotech Genfit came up with IPO filings. Cardiovascular disease device maker ShockWave Medical, Diamondback midstream services unit Rattler Midstream LP, and NASH biotech Cirius Therapeutics are also on their way for a March IPO. Renaissance IPO ETF (IPO - Free Report) was up 14% in the past month (read: Will IPO ETFs Sizzle in 2019?).
Brexit Could Be Delayed
Amid huge internal differences, the UK parliament is now likely to decide between “no deal” and delay in Brexit. If the no-deal option is voted down, the Commons in the U.K. will have a chance to request prime minister May for an extension to Article 50, postponing Brexit by a few months, per an article published on CNN. However, France and Spain already signed their disapproval to a likely last-minute request for a two-month extension of the Brexit (read: Brexit Delay in the Cards? Europe ETFs to Rally).
If Brexit delays, several Europe-related ETFs likeInvesco CurrencyShares British Pound Sterling (FXB - Free Report) , First Trust Europe Alphadex FundFEP, Europe Smallcap Dividend WisdomtreeDFE and Europe Financials iShares MSCI ETF (EUFN - Free Report) should go higher.
Want key ETF info delivered straight to your inbox?
Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Top ETF Stories of February
After a spectacular January, the second month of 2019 also turned out positive for Wall Street with SPDR S&P 500 ETF (SPY - Free Report) , SPDR Dow Jones Industrial Average ETF (DIA - Free Report) and Invesco QQQ ETF (QQQ - Free Report) adding about 3.4%, 4% and 3.7%, respectively. Overall, the broader market was charged up and iShares Core S&P Total US Stock Mkt ETF ITOT gained about 6.1% past month (as of Feb 27, 2019).
In fact, February’s performance positioned the S&P 500 for its best year-to-date performance in more than three decades, per financial times. The S&P 500 has recoiled sharply this year from the Christmas slump and is now less than 5% away from its record high five months ago as indicated by financial times.
Against this backdrop, let’s delve a little deeper into the key ETF events of February that helped Wall Street maintain its 2019 mojo.
Dovish Fed
The Fed minutes from the Jan 29-30 meeting confirms the patient view of the central bank toward future rates hike. The Fed started offering a dovish tone from the start of this year, which is one of key reasons for the market rally. A dovish Fed has kept Invesco DB US Dollar Bullish (UUP) (up 0.6% past month) at a subdued level.
U.S.-China Trade Relation: Peaks & Valleys
Apparently, the month was all about U.S.-China trade optimism. On Feb 25, President Donald Trump even announced a delay in the increase of tariffs to 25% on about $200 billion worth of Chinese goods, citing “substantial progress” in trade talks with Beijing (read: Top Performing ETF Areas of February).
With this, the year-long trade dispute between the world’s biggest economies was thought to be reaching a conclusion. However, there was skepticism too in the U.S.-China trade relation. At month-end, U.S. trade representative Robert Lighthizer told Congress that the disagreement between both countries “was too serious to be solved by promises by China to buy more US products.”
Whatever the case, China ETFs were clear winners in the month. Global X MSCI China Information Tech ETF CHIK, VanEck Vectors ChinaAMC SME-ChiNext ETF (CNXT - Free Report) and VanEck Vectors ChinaAMC CSI 300 ETF returned in the range of 15% to 20%.
Zero-Fee ETF to Hit Market?
In late February, Social Finance Inc., an online lender also known as SoFi, made headlines by proposing two ETFs that will waive off managed fees for at least the first year of operation. Not only this, renowned issuer Vanguard also cut fees of the 10 key ETFs like Vanguard FTSE Emerging Markets ETF (VWO - Free Report) as part of the ongoing fee war trend (read: Zero-Fee ETFs to Hit the Market Finally?).
M&A Holds Up Biotech Sector
A solid merger-and-acquisition momentum has been instrumental in the biotech rally this year. February was no exception as Swiss pharma giant Roche Holdings (RHHBY - Free Report) announced the acquisition of the U.S.-based gene therapy company Spark Therapeutics for $4.8 billion (read: Biotech ETFs Jump on Roche-Spark Deal).
Principal Healthcare Innovators Index ETF BTEC, ALPS Medical Breakthroughs ETF (SBIO - Free Report) and Virtus LifeSci Biotech Products ETF BBP are some of the winners in the month, having gained around 10% each.
Marijuana Maintains its Mojo
Pot stocks are on a tear this year on positive industry-specific news and renewed risk appetite. February’s key tailwind in the marijuana market was Canadian cannabis firm Tilray Inc.’s TLRY announcement of acquisition of the world’s largest hemp food maker Manitoba Harvest for $318 million. Growing efforts of inducing cannabis in food, beverage, tobacco and beauty products explain the 15% one-month gains in ETFMG Alternative Harvest ETF MJ (read: Tilray's Deal to Buy Hemp Food Maker Bolsters Marijuana ETF).
Busy U.S. IPO Market
Just as the government reopened, the U.S. IPO market charged up in February. In late February, Up Fintech and NASH biotech Genfit came up with IPO filings. Cardiovascular disease device maker ShockWave Medical, Diamondback midstream services unit Rattler Midstream LP, and NASH biotech Cirius Therapeutics are also on their way for a March IPO. Renaissance IPO ETF (IPO - Free Report) was up 14% in the past month (read: Will IPO ETFs Sizzle in 2019?).
Brexit Could Be Delayed
Amid huge internal differences, the UK parliament is now likely to decide between “no deal” and delay in Brexit. If the no-deal option is voted down, the Commons in the U.K. will have a chance to request prime minister May for an extension to Article 50, postponing Brexit by a few months, per an article published on CNN. However, France and Spain already signed their disapproval to a likely last-minute request for a two-month extension of the Brexit (read: Brexit Delay in the Cards? Europe ETFs to Rally).
If Brexit delays, several Europe-related ETFs like Invesco CurrencyShares British Pound Sterling (FXB - Free Report) , First Trust Europe Alphadex Fund FEP, Europe Smallcap Dividend Wisdomtree DFE and Europe Financials iShares MSCI ETF (EUFN - Free Report) should go higher.
Want key ETF info delivered straight to your inbox?
Zacks’ free Fund Newsletter will brief you on top news and analysis, as well as top-performing ETFs, each week. Get it free >>